Enlivex Therapeutics (ENLV) Investor presentation summary

Dual engine business model

• Operates with a hybrid model combining a digital asset treasury and clinical-stage longevity therapeutics.

• Largest institutional holder of RAIN, a governance token for decentralized prediction markets.

• Treasury strategy aims to generate non-dilutive capital for clinical development via deflationary tokenomics and active yield.

• $212M private placement in 2025 enabled the prediction market treasury strategy.

• Holds an exclusive option to acquire up to $898M in RAIN tokens at a fixed price, expiring in 2027.

Prediction markets and RAIN protocol

• RAIN is a leading prediction market and options protocol on Arbitrum, enabling permissionless market creation and decentralized governance.

• Protocol features a 5% fee, with 2.5% allocated to buyback and burn, reducing token supply.

• Forecasts project $2.5B in cumulative RAIN supply reduction by 2030, with a $1T prediction market trading volume and 5% RAIN market share.

• RAIN is listed on major exchanges, with plans for a top-5 exchange listing in H1 2026 to enhance liquidity and price discovery.

• Ecosystem expansion includes SDK/API releases, developer programs, and global campaigns to drive adoption and institutional awareness.

Financial performance and treasury management

• Estimated RAIN portfolio value at year-end 2025 is $607M, with a $363M gain in 2025.

• Option to purchase additional RAIN tokens valued at $1.7B as of December 2025, with a $1.26B change in fair value during the year.

• Asset manager employs yield-enhancement strategies, including protocol staking, restaking, and selective DeFi deployment.

• Treasury metrics are updated and available on the company’s website.